Novel Substituted Indazoles as Small Molecule-Based Inhibitors of KRAS Proteins
Jian Rong1,2, Steven H Liang2
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, P. R. China.
Abstract:
This patent discloses a series of substituted indazole compounds as novel inhibitors of KRAS, with potential utility as anticancer therapeutics. The invention describes the chemical structures of these substituted indazoles, their pharmaceutical compositions, and methods of use for treating KRAS-driven malignancies. The disclosed compounds are designed to modulate oncogenic KRAS signaling and may offer a new therapeutic strategy for cancers associated with KRAS mutations.
Related Concept Videos
Inhibition of Cdk Activity
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:


